Welcome to our dedicated page for Allovir news (Ticker: ALVR), a resource for investors and traders seeking the latest updates and insights on Allovir stock.
The AlloVir, Inc. (ALVR) news page on Stock Titan aggregates company communications and third-party coverage related to its activities as an allogeneic T cell immunotherapy developer and its planned merger with Kalaris Therapeutics, Inc. AlloVir describes itself as a late-clinical stage cell therapy company focused on restoring natural immunity against life-threatening viral diseases in immunocompromised pediatric and adult patients. Its disclosures highlight an off-the-shelf, allogeneic virus-specific T cell platform and a pipeline led by the multi-virus-specific T cell therapy posoleucel.
Readers following ALVR news can find updates on clinical trial progress and outcomes, including Phase 2 and Phase 3 studies of posoleucel in allogeneic hematopoietic cell transplant recipients and adult kidney transplant recipients with BK viremia. Company releases have discussed prevention and treatment trials targeting adenovirus, BK virus, cytomegalovirus, Epstein-Barr virus, human herpesvirus-6, and JC virus, as well as early-stage work on ALVR106 for respiratory viruses and ALVR107 for chronic hepatitis B infection.
News items also cover strategic and corporate developments. AlloVir has reported discontinuation of its three Phase 3 posoleucel studies after pre-planned futility analyses, along with a shift toward capital preservation and review of strategic alternatives. Subsequent announcements describe a definitive all-stock merger agreement with Kalaris Therapeutics, stockholder approval of that merger, and expectations that the combined company will operate as Kalaris Therapeutics, Inc. and trade on Nasdaq under the ticker KLRS, subject to customary closing conditions.
In addition, the ALVR news feed may include information on financings, investor conference participation, and regulatory designations such as RMAT, Orphan Drug, and PRIME status for posoleucel. Investors and researchers can use this page to monitor how AlloVir’s virus-specific T cell programs and its transition toward a retina-focused combined company with Kalaris are described over time.
AlloVir (ALVR) announced its participation in the upcoming Transplantation & Cellular Therapy Meeting, which will take place virtually from February 8 to 12, 2021. The company will present three oral presentations and one poster presentation, addressing critical topics related to virus-associated complications in patients post-transplantation. The presentations will cover economic burdens and treatment advancements for viral infections, including the use of allogeneic, off-the-shelf T cells targeting COVID-19. This highlights AlloVir's ongoing commitment to improving outcomes for patients with weakened immune systems.
AlloVir, Inc. (Nasdaq: ALVR) will present a corporate overview at the 39th Annual J.P. Morgan Healthcare Conference on January 11, 2021, at 9:10 a.m. ET. An audio-only webcast will be available on the AlloVir website, with an archived replay accessible for 30 days post-event. AlloVir specializes in late clinical-stage cell therapy, focusing on restoring immunity against severe viral diseases in immunocompromised patients using innovative T cell technology. The company is actively advancing multiple mid- and late-stage clinical trials across its product portfolio.
AlloVir (Nasdaq: ALVR) has received FDA clearance for its Investigational New Drug application for ALVR106, an off-the-shelf virus-specific T cell therapy targeting respiratory syncytial virus (RSV), influenza, parainfluenza virus, and human metapneumovirus. This clearance allows AlloVir to start a Phase 1/2 proof-of-concept clinical trial in hematopoietic stem cell transplant patients suffering from these viral infections. ALVR106 aims to significantly reduce morbidity and mortality rates associated with respiratory infections in high-risk patients.
AlloVir focuses on restoring natural immunity using innovative cell therapy for patients with weakened immune systems. The company leverages proprietary technology to create allogeneic, multi-virus specific T cells aimed at tackling serious viral diseases. It is currently advancing multiple mid- and late-stage clinical trials within its product portfolio, positioning itself as a leader in the biotechnology sector.
AlloVir (Nasdaq: ALVR) announced encouraging results from its Phase 2 CHARMS study, where its T cell therapy, Viralym-M (ALVR105), showed a 93% clinical response among allo-HSCT patients with drug-refractory viral infections. The data, presented at the 62nd ASH Annual Meeting, demonstrated the treatment was well-tolerated, addressing critical needs in immunocompromised patients facing significant viral infection risks. Additionally, findings highlighted the economic burden of virus-associated hemorrhagic cystitis (V-HC), stressing the need for effective therapies.
AlloVir (Nasdaq: ALVR) has announced promising preclinical data for ALVR109, a T cell therapy targeting SARS-CoV-2, presented at the 62nd ASH Annual Meeting. This therapy demonstrated the ability to selectively kill virus-infected cells while sparing healthy ones, potentially aiding high-risk COVID-19 patients. A clinical trial is underway at Baylor College of Medicine and collaborating hospitals. The company aims to assess ALVR109's safety and efficacy, emphasizing the importance of healthy SARS-CoV-2-specific T cells in combating severe disease.
AlloVir, Inc. (Nasdaq: ALVR) will present a corporate overview at the Piper Sandler 32nd Annual Virtual Healthcare Conference on December 1, 2020. The presentation will be available to registered attendees from November 23 to December 3, and an archived replay will be accessible for about 30 days afterward. Specializing in cell therapy, AlloVir aims to restore immunity against serious viral diseases in immunocompromised patients using its proprietary T cell technology. This innovative approach targets multiple viruses in a single treatment.
AlloVir (Nasdaq: ALVR) completed its initial public offering, raising $317.7 million in gross proceeds, establishing a strong financial base for growth. The company initiated its Phase 1/2 clinical trial for ALVR109, targeting high-risk COVID-19 patients, and is on track to start Viralym-M studies for virus-associated hemorrhagic cystitis and prevention of multiple viral infections by year-end. Additionally, AlloVir is transferring its T-cell manufacturing process to ElevateBio BaseCamp to enhance production capacity.
AlloVir (Nasdaq: ALVR) announced presentations of three abstracts during the 62nd American Society of Hematology Annual Meeting on December 5-8, 2020. The highlights include:
- COVID-19 Treatment: Allogeneic T cells targeting SARS-CoV-2 presented on December 7.
- Viral Infections: Results from a phase 2 study of multi-virus T cell therapy following HSCT, also on December 7.
- Economic Burden: A study on the clinical impact of virus-associated hemorrhagic cystitis on December 7.
AlloVir focuses on restoring immunity against life-threatening viral diseases in vulnerable patients.
AlloVir (Nasdaq: ALVR) presented findings at IDWeek™ 2020 indicating significantly higher healthcare costs and worse clinical outcomes due to respiratory virus infections in patients post-allogeneic hematopoietic cell transplantation (allo-HCT). Analysis of claims data from 13,363 patients showed median reimbursements were $132,395 higher for patients with any respiratory virus infection (RVI) compared to those without. The risk of all-cause mortality was also significantly associated with RVI. The poster presentation revealed increasing costs and clinical complications with each additional viral infection.
FAQ
What is the current stock price of Allovir (ALVR)?
What is the market cap of Allovir (ALVR)?
